← Browse by Condition
Medical Condition
gastroesophageal junction adenocarcinoma
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for gastroesophageal junction adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — gastroesophageal junction adenocarcinoma Clinical Trials
How many clinical trials are currently recruiting for gastroesophageal junction adenocarcinoma?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for gastroesophageal junction adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for gastroesophageal junction adenocarcinoma?
gastroesophageal junction adenocarcinoma research spans Phase 1 (4 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a gastroesophageal junction adenocarcinoma clinical trial?
Eligibility criteria for gastroesophageal junction adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 4
Phase 2 3
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06324357 Phase 1, Phase 2
Recruiting
Enrollment
768 pts
Location
United States, Belgi...
Sponsor
Boehringer Ingelheim
NCT04361708 Phase 1
Recruiting
Enrollment
54 pts
Location
United States
Sponsor
University of Chicago
NCT06773312 Phase 1
Recruiting
Enrollment
80 pts
Location
China
Sponsor
Sichuan Luzhou Buchang Biophar...
NCT06131840 Phase 1
Recruiting
Enrollment
914 pts
Location
United States, Canad...
Sponsor
Seagen, a wholly owned subsidi...
NCT04510129
Recruiting
Enrollment
1,650 pts
Location
United States
Sponsor
Cofactor Genomics, Inc.
NCT04656041 Phase 2
Recruiting
Enrollment
40 pts
Location
United States
Sponsor
Massachusetts General Hospital
NCT06038578 Phase 2
Recruiting
Enrollment
146 pts
Location
United States, Japan...
Sponsor
Toray Industries, Inc
Related Conditions
colorectal cancer (2) metastatic breast cancer (1) metastatic gastric adenocarcinoma (1) esophageal adenocarcinoma (1) pancreatic adenocarcinoma (1) adenocarcinoma (1) advanced or metastatic gastric cancer (1) colorectal neoplasms (1) carcinoma non small cell lung (1) stomach neoplasms (1) pancreatic ductal adenocarcinoma (1) small cell lung carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology